Subdermal Contraceptive Implants Market Size, Share & Trends Analysis Report By Product (Etonogestrel Implant, Levonorgestrel Implant), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global subdermal contraceptive implants market size was valued at USD 1.05 billion in 2023 and is projected to grow at a CAGR of 7.5% from 2024 to 2030. The driving factors of the growth include rising demand for reliable contraceptives, unintended pregnancies, and increasing awareness of sexual health and family planning. The rise in unintended pregnancies is a major driver for the increasing demand for subdermal contraceptive implants. According to the United Nations Population Fund (UNFPA) data published in March 2022, the number of unintended pregnancies was estimated to be about 121 million. Such an increased number demands the use of long-term contraceptives to prevent unintended cases and drive market growth.

In addition, the rise in unintended pregnancies may also lead to increasing abortions. For instance, according to the United Nations Population Fund (UNFPA) information published in March 2022, nearly 60% of these unintended pregnancies end in abortions, accounting for 45% of unsafe abortions, causing 5% to 13% of maternal deaths. This further increases the need for reliable and effective contraceptives, such as subdermal contraceptive implants.

The rapid rise in population poses significant challenges to the development of a nation. According to the World Health Organization (WHO) report published in September 2023, nearly 1.1 billion women pose a need for family planning, and about 874 million are using modern contraceptive methods to prevent unintended pregnancies. The need for family planning demands modern solutions such as subdermal contraceptive implants for long-term birth control, boosting the market growth.

Product Insights

Etonogestrel implants dominated the market and accounted for a share of 64.6% in 2023. The driving factors of etonogestrel implants are rising unintended pregnancies and unsafe abortions. According to the United Nations report published in 2022, it was estimated that 164 million women wish to delay or avoid pregnancy. The implant is suitable for patients seeking long-term efficiency against pregnancies and is less expensive compared with other contraceptives in case of long-term usage. According to data from the University of Iowa published in October 2023, the implant can prevent pregnancy 99% of the time, with the effect lasting up to four years. The long-term effect and lower probability of causing failure than other contraceptives boost the segment growth. Some etonogestrel implants available in the market are Implanon and Nexplanon.

The levonorgestrel Implant segment is expected to grow significantly during the forecast period. The factors primarily driving the segment growth are the need for family planning and unintended pregnancies, leading to the rising number of unsafe abortions. The levonorgestrel implant is used to prevent pregnancy for up to five years through continuous hormone release. The lower rate of failure and efficacy of up to five years make it a suitable choice of contraceptive for women who wish to delay their pregnancy, driving the segment market. Jadelle is the levonorgestrel implant available in the market.

Distribution Channel Insights

The hospital segment dominated the market and accounted for a share of 54.4% in 2023. The hospital is a suitable place where patients can get their various tests done and have doctor’s consultations, which boosts the segment growth. The hospitals are medically equipped with advanced technologies, enhancing the quality of service. In addition, the hospitals offer integrated healthcare under one roof, from examinations, to counseling and conducting procedures for subdermal contraceptive implants. The subdermal contraceptive implant can be completed only by healthcare professionals under their guidance. These advantages boost the market growth of the segment.

The gynecology clinics segment is expected to register the fastest CAGR over the forecast period. The factors driving the segment growth include the number of rising abortions and healthcare consultations that can be taken at the gynecologist clinic. The gynecology clinics play a crucial role in offering consultations to this form of advanced contraceptive. The clinics offer end-to-end services such as consultation from the specialist, gynecology examinations, conducting abortions, contraceptive implant procedures, and follow-up care. The gynecology clinics ensure the implant procedure is performed under skilled professionals and minimize the risk of further complications. These advantages are likely to drive segment growth over the forecast period.

Regional Insights

North America subdermal contraceptive implants market dominated the market in 2023. The factors driving the market growth include the rise in unintended pregnancies, the increasing number of gynecology clinics, and government initiatives. For instance, according to the government of Canada data of August 2022, nearly 257 million women wish to avoid pregnancy. The government of Canada is taking initiatives to reduce these numbers and create sexual health awareness. For instance, the government of Canada information published in May 2024 announced the launching of the first phase of the national pharma plan with USD 1.5 billion in federal investment. Under this plan, the government plans on making contraceptive medications and devices free of cost, including birth control pills, IUDs, and contraceptive implants. Such initiatives are expected to drive market growth.

U.S. Subdermal Contraceptive Implants Market Trends

The U.S. subdermal contraceptive implants market accounted for a 60.5% share of the global market in 2023. The market growth in the country is attributed to the rising number of abortions and unintended pregnancies. According to the U.S. Department of Health and Human Services, about half of pregnancies in the country are unintended, leading to preterm birth and postpartum depression. The Healthy People 2030 initiative focuses on decreasing the number of unintended pregnancies and abortions by promoting the use of contraceptives. Such initiatives are further expected to add to the market growth.

Europe Subdermal Contraceptive Implants Market Trends

Europe accounted for a significant market share in 2023 in the subdermal contraceptive implants market. The driving factors primarily contributing to the market growth are higher abortion rates due to unintended pregnancies and government initiatives taken to reduce this rising number. For instance, according to The Luxembourg Government data published in March 2023, full reimbursement for contraceptives would be provided. In addition, in the Contraceptive Policy Atlas Europe 2024, about 22 countries cover long-term efficacy reversible contraceptives such as implants, IUDs, and injectables in their national health system.

The market growth of subdermal contraceptive implants in the UK is attributed to the higher rate of unintended pregnancies in the nation. For instance, according to the data published by University College London (UCL) in October 2021, the country saw cases of unplanned pregnancies doubled during the COVID-19 pandemic lockdown. According to the government of the UK, data published in August 2022, under the Women Health Strategy for England, the government plans to focus on increasing access to long-acting reversible contraceptives such as implants and IUDs. Initiatives to increase the adoption of contraceptive implants are expected to boost the market growth.

Asia Pacific Subdermal Contraceptive Implants Market Trends

Asia Pacific subdermal contraceptive implants market is estimated to register the fastest CAGR over the forecast period. The factors driving the market growth in the region are attributed to the growing number of unintended pregnancies, leading to unsafe abortions. For instance, according to The Economic and Social Commission for Asia and the Pacific (ESCAP) data 2023, 13 million unplanned pregnancies were estimated. The Contraceptive Policy Atlas in November 2023 launched a call of action in the region to identify the need for contraceptives, including long-acting reversible contraceptives such as implants and IUDs. In addition, companies such as Shanghai Dahua Pharmaceutical Co., Ltd. offer subdermal contraceptive, implants such as sino-implant II, available in the market under the brand name Levoplant, registered in about 40 countries. Such government policies and companies offering products are expected to drive market growth.

According to the United Nations Population Fund (UNFPA) data published in March 2022, one in seven unintended pregnancies occurs in India. The government of India is implementing initiatives to curb the number of population and reduce unintended pregnancies leading to abortions. For instance, the government of India has expanded the use of contraceptives under the National Family Planning Program, including the adoption of subdermal contraceptive implants in 2023. Such initiatives are expected to boost market growth.

Key Subdermal Contraceptive Implants Company Insights

Some key companies in the subdermal contraceptive implants market include Bayer AG, Merck & Co. Inc., and Shanghai Dahua Pharmaceutical Co., Ltd. Key companies are involved in strategic initiatives such as in innovating new products, collaborating with institutions and other industries, and establishing partnerships.

• Bayer AG is a Germany-based global life science company that produces and markets healthcare and agricultural products. The company is involved in women healthcare products such as modern contraceptives including pills, intrauterine systems, patches, vaginal rings and implants.

• Merck & Co. Inc. is a biopharmaceutical company involved in research to deliver innovative health solutions for the prevention and treatment of people. The company is involved in subdermal contraceptive implants such as NEXPLANON and operates in the pharmaceutical, animal health, and consumer healthcare sectors.

Recent Developments

• In February 224, Bayer AG and DARÉ BIOSCIENCE collaborated to expand an innovative hormone-free monthly contraceptive.

• In April 2022, ProMed announced the initialization of preclinic evaluation of resorbable contraceptive implants, a project funded by the Bill & Melinda Gates Foundation.

Subdermal Contraceptive Implants Market Report Scope

Global Subdermal Contraceptive Implants Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global subdermal contraceptive implants market report based on product, distribution channel, and region:

• Product Outlook: (Revenue, USD Million, 2018 - 2030)

  • Etonogestrel Implant

  • Levonorgestrel Implant

• Distribution Channel Outlook: (Revenue, USD Million, 2018 - 2030)

  • Hospital

  • Gynecology Clinics

  • Community Health Care Centres

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • KSA

    • UAE

    • Kuwait